The head of the US Food and Drug Administration’s division of vaccines and gene therapies is leaving the agency after a tumultuous tenure, sending biotech shares higher in late trading on Friday.
The end of Prasad’s tenure is “a sigh of relief” for the biotech industry, BMO Capital ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
